Cargando…

Dapagliflozin Improved Cardiac Function and Structure in Diabetic Patients with Preserved Ejection Fraction: Results of a Single Centre, Observational Prospective Study

Sodium-glucose cotransporter inhibitors (SGLT2i) have demonstrated a reduction in cardiovascular events in diabetes and heart failure (HF). The mechanisms underlying this benefit are not well known and data are contradictory. The purpose of this study is to analyse the effect of dapagliflozin on car...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cortés, Marcelino, Lorenzo, Oscar, Lumpuy-Castillo, Jairo, Martínez-Albaladejo, Sacramento, Taibo-Urquía, Mikel, Pello, Ana María, Bollas, Antonio José, Orejas, Miguel, Navas, Miguel Ángel, Macia, Ester, Martínez, María Esther, Rueda, Andrea, Tuñón, Jose
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607224/ https://www.ncbi.nlm.nih.gov/pubmed/37892836 http://dx.doi.org/10.3390/jcm12206698

Ejemplares similares

Cardiovascular Damage in COVID-19: Therapeutic Approaches Targeting the Renin-Angiotensin-Aldosterone System
por: Lumpuy-Castillo, Jairo, et al.
Publicado: (2020)

Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy
por: Devesa, Ana, et al.
Publicado: (2021)

Beta-blocker therapy in elderly patients with renal dysfunction and heart failure
por: Martínez-Milla, Juan, et al.
Publicado: (2021)

The role of bioimpedance analysis in overweight and obese patients with acute heart failure: a pilot study
por: Venegas‐Rodríguez, Ana, et al.
Publicado: (2023)

Potential Role of the mTORC1-PGC1α-PPARα Axis under Type-II Diabetes and Hypertension in the Human Heart
por: Hang, Tianyu, et al.
Publicado: (2023)

Comparison of pharmacological treatment alone vs. treatment combined with implantable cardioverter defibrillator therapy in patients older than 75 years
por: Cortés, Marcelino, et al.
Publicado: (2018)

Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF
por: Butt, Jawad H., et al.
Publicado: (2021)

Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2022)

Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance
por: Taberner-Cortés, Alida, et al.
Publicado: (2020)

Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index
por: Adamson, Carly, et al.
Publicado: (2021)

Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial
por: Vardeny, Orly, et al.
Publicado: (2022)

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
por: Solomon, Scott D., et al.
Publicado: (2021)

Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Jackson, Alice M., et al.
Publicado: (2020)

Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
por: Chatur, Safia, et al.
Publicado: (2023)

Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?
por: Williams, David M., et al.
Publicado: (2020)

Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction
por: Isaza, Nicolas, et al.
Publicado: (2021)

Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction
por: Blair, Hannah A.
Publicado: (2021)

Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction
por: Amiguet, Martina, et al.
Publicado: (2023)

Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF
por: Jhund, Pardeep S., et al.
Publicado: (2021)

An accessory chord in a wrong place
por: Arroyo Rivera, Belen, et al.
Publicado: (2019)

Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study
por: Hao, Zhengyang, et al.
Publicado: (2022)

Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2020)

Improvement in quality of life with sacubitril/valsartan in cardiac resynchronization non-responders: The RESINA (RESynchronization plus an Inhibitor of Neprilysin/Angiotensin) registry
por: Campal, José Manuel Rubio, et al.
Publicado: (2021)

Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF
por: Dewan, Pooja, et al.
Publicado: (2021)

Prevalence and prognostic value of monoclonal gammopathy in heart failure patients with preserved ejection fraction: A prospective study
por: Devesa, Ana, et al.
Publicado: (2022)

Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF
por: Jhund, Pardeep S., et al.
Publicado: (2020)

Cost‐utility analysis of add‐on dapagliflozin in heart failure with reduced ejection fraction in the Philippines
por: Mendoza, Victor L., et al.
Publicado: (2021)

Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial
por: Kosiborod, Mikhail N., et al.
Publicado: (2020)

Direct actions of dapagliflozin and interactions with LCZ696 and spironolactone on cardiac fibroblasts of patients with heart failure and reduced ejection fraction
por: Ortega‐Paz, Luis, et al.
Publicado: (2022)

Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report
por: Martínez-Montoro, José Ignacio, et al.
Publicado: (2022)

Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy
por: González-Clemente, José M., et al.
Publicado: (2022)

Dapagliflozin Impact on the Exercise Capacity of Non-Diabetic Heart Failure with Reduced Ejection Fraction Patients
por: Reis, João, et al.
Publicado: (2022)

Cost‐utility analysis of add‐on dapagliflozin in heart failure with preserved or mildly reduced ejection fraction
por: Tang, Yi, et al.
Publicado: (2023)

Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF
por: Yeoh, Su Ern, et al.
Publicado: (2023)

Absence of High Lipoprotein(a) Levels Is an Independent Predictor of Acute Myocardial Infarction without Coronary Lesions
por: Kallmeyer, Andrea, et al.
Publicado: (2023)

The early effect of dapagliflozin on strain and tissue Doppler parameters of diastolic function in diabetic patients with heart failure with reduced ejection fraction
por: Maragkoudakis, Spyridon, et al.
Publicado: (2021)

Anti-Inflammatory Drugs in Patients with Ischemic Heart Disease
por: Pello Lázaro, Ana María, et al.
Publicado: (2021)

Diagnostic approaches for diabetic cardiomyopathy
por: Lorenzo-Almorós, A., et al.
Publicado: (2017)

Cost‐effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China
por: Yao, Younan, et al.
Publicado: (2020)

Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach
por: Nessler, Jadwiga
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v8l2ofngnno4nu1qria787ub86